H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a price target of $55.00 for the company. The full article content is only available to premium subscribers.
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Harmony Biosciences reported its Q1 financial results and reaffirmed its 2026 net revenue guidance of over $1 billion. The company also reinforced its strategic priorities for 2026. This announcement indicates the company's confidence in its future financial performance and strategic direction.
Harmony Revenue Rises as WAKIX Franchise Expands
Harmony Biosciences reported a 17% revenue increase for its narcolepsy drug WAKIX in the first quarter, reaching $215.4 million, and reaffirmed its full-year revenue guidance between $1 billion and $1.04 billion. The company is actively expanding its WAKIX franchise through patent litigation, new formulations like pitolisant GR and HD, and pipeline programs such as BP-205 and EPX-100, aiming for durability into the 2030s. Despite a decline in net income due to licensing expenses, Harmony secured FDA approval for a pediatric cataplexy indication for WAKIX and ended the quarter with $870.5 million in cash.
A beaten-down biotech just lost a meaningful backer — should you care?
Bridge City Capital, LLC, has fully divested its investment in Harmony Biosciences Holdings (NASDAQ:HRMY) during the first quarter of 2026, selling all 237,103 shares for an estimated $7.77 million. Harmony Biosciences, a healthcare company, focuses on developing treatments for rare neurological diseases and aims to address unmet medical needs in the U.S. market. This complete exit by a significant backer might raise questions about the implications for the biotech firm's future.
Harmony Biosciences (HRMY) director receives 21,872-share stock option grant
Harmony Biosciences director Linda M. Szyper was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. This grant serves as compensation, not an open-market purchase, and vests fully on the earlier of May 14, 2027, or the next annual meeting, contingent on her continued service. Following this transaction, Szyper holds 21,872 derivative securities of Harmony Biosciences common stock.
Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3
Harmony Biosciences Holdings, Inc. director Germano Geno J has filed an initial Form 3 with the SEC, which officially lists him as a reporting person for the company. This filing is a mandatory first insider ownership report for company officers, directors, and large shareholders. It establishes his reporting status but does not indicate any current share transactions or beneficial ownership.
Harmony Biosciences (HRMY) director granted 21,231 stock options
Harmony Biosciences Holdings, Inc. director Germano Geno J was granted 21,231 stock options as equity compensation. These options, with an exercise price of $30.76 per share and an expiration date of May 14, 2036, will vest in 36 equal monthly installments starting on June 14, 2026. This transaction is a compensation grant and not an open-market purchase or sale.
Harmony Biosciences director granted 21,872 options | HRMY Insider Trading
Harmony Biosciences director Philip Ron M was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. The options will vest in full by May 14, 2027, or the date of the next annual meeting, contingent on his continued service. This transaction is a compensation-related award, not an open-market purchase or sale.
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) reported a dip in net income for Q1 2026, though net product revenue grew by 17%. The company is focused on WAKIX, having received FDA approval for pediatric cataplexy and actively pursuing patent protection into 2030, despite near-term earnings pressure. Investors should consider the company's reliance on WAKIX and ongoing patent litigation as key factors influencing its investment narrative.
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) experienced a dip in Q1 2026 net income, yet reported 17% net product revenue growth and secured FDA approval for a pediatric cataplexy indication for WAKIX. The company faces ongoing patent litigation for WAKIX, which is crucial for its revenue guidance, and investors are advised to consider the long-term implications of these legal disputes and potential generic competition. Despite an earnings miss, the investment narrative still largely hinges on WAKIX's performance and patent protection, with analysts predicting future revenue and earnings growth.
Number of shareholders of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY
This article provides limited information regarding the number of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), indicating that data for specific periods and values can be accessed. It also notes various market data and reference data providers while listing copyright information from FactSet and the American Bankers Association.
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) reported a dip in first-quarter 2026 net income to US$32.49 million, down from US$45.56 million a year prior, despite a 17% net product revenue growth. The company is focusing on WAKIX performance and patent protection, particularly with the recent FDA approval for a pediatric cataplexy indication expanding the patient base and active litigation to protect WAKIX patents until 2030 forming a critical investment consideration. Analysts are divided on future revenue and earnings projections, with some more optimistic on growth beyond the current consensus.
Harmony Biosciences Shareholders Approve Governance Measures at Meeting
Harmony Biosciences Holdings (HRMY) shareholders recently approved key governance measures at their 2026 Annual Meeting. They elected four Class III directors, ratified Deloitte & Touche LLP as the independent auditor, and endorsed executive compensation, indicating strong shareholder support for current leadership. The company focuses on developing therapies for rare neurological diseases, with an average trading volume of 1,009,503 and a current market cap of $1.75 billion.
Harmony Biosciences (HRMY) shareholders elect directors, ratify auditor and back pay
Harmony Biosciences Holdings, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected four Class III directors, ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the compensation of the company’s named executive officers on a non-binding, advisory basis. All proposals presented at the meeting passed with significant shareholder support, as detailed in the company's 8-K filing.
Harmony Biosciences’ Four Key Pillars to Drive Value Creation
Harmony Biosciences reported a strong 17% year-over-year growth for WAKIX in Q1 2026, reaching $215.4 million in net revenue and reaffirming its full-year guidance of over $1 billion. The company has outlined four strategic pillars to drive long-term value: protecting and growing the pitolisant franchise, advancing pipeline assets like BP-205, and emphasizing business development for opportunities with revenue potential between 2028 and 2032. These initiatives aim to ensure sustained growth and deliver innovative treatments for patients while creating shareholder value.
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality
Harmony Biosciences Holdings' recent earnings announcement showed soft headline numbers, but underlying factors suggest a positive outlook. The company's accrual ratio of -0.32 indicates that its free cash flow significantly exceeded its statutory profit, producing US$276m in free cash flow compared to US$145.6m in reported profit. This strong conversion of profit to free cash flow suggests that Harmony Biosciences Holdings' true earnings potential might be better than its statutory profit indicates, despite a recent decline in EPS.
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Liquidia Technologies (LQDA)
Two healthcare companies, Harmony Biosciences Holdings (HRMY) and Liquidia Technologies (LQDA), recently received bullish sentiments from analysts. H.C. Wainwright reiterated a Buy rating for Harmony Biosciences with a $55.00 price target, highlighting a 42.1% upside from current levels. Liquidia Technologies also maintained a Buy rating from H.C. Wainwright, with a price target of $67.00, representing a 20.3% upside.
(HRMY) Volatility Zones as Tactical Triggers
This article provides an AI-driven analysis for Harmony Biosciences Holdings Inc. (HRMY), highlighting weak near-term sentiment and a significant risk-reward short setup. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report also encourages users to sign up for full access to real-time signals and personalized alerts.
Harmony Biosciences Holdings (HRMY) Announces Financial Results for Q1 2026
Harmony Biosciences Holdings (HRMY) reported Q1 2026 financial results, with net product revenue of $215.4 million, a 17% year-over-year increase, and is on track for over $1 billion in full-year net revenues. Despite strong demand, the company faced market access headwinds and a 39% increase in the cost of products sold. Harmony Biosciences also received FDA approval for a pediatric cataplexy indication and is actively protecting its WAKIX intellectual property.
Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
Harmony Biosciences Holdings, Inc. reported a Q1 earnings miss, with statutory EPS falling 21% below expectations, despite revenues being only slightly lower than forecast. Despite the miss, analysts have largely maintained their previous revenue and EPS forecasts for 2026, leading to an unchanged consensus price target, suggesting the company's long-term prospects remain in line with earlier expectations. The company's revenue growth is projected to slow compared to historical rates but is still expected to outpace the industry average.
Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
Harmony Biosciences Holdings, Inc. reported a Q1 earnings miss, with revenue 2.5% lower and EPS 21% below analyst expectations. Despite this, analysts have not significantly changed their 2026 forecasts for revenue ($1.01b) or EPS ($3.52), maintaining a consensus price target of $44.36. The company's revenue growth is projected to slow to 17% annually but is still expected to outpace the industry average.
10 Best Healthcare Stocks to Buy for the Long Term
This article identifies Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) as one of the best healthcare stocks for long-term investment. The company reported strong Q1 2026 financial results with significant year-over-year revenue growth, projecting over $1 billion in net revenues for the full year. Harmony Biosciences also recently received FDA approval for a pediatric cataplexy indication for its product WAKIX and is actively defending its intellectual property.
Harmony Biosciences Holdings HRMY Margin Compression Challenges Bullish Valuation Narratives
Harmony Biosciences Holdings (HRMY) is facing margin compression, with its net margin dropping to 16.2% from 20.5% in the prior year, despite positive net income and EPS. While the company trades at a P/E of 12.5x, below the industry average, its projected earnings and revenue growth rates are below market averages, and there are concerns about its reliance on a single product. These factors create a mixed valuation picture, challenging overly bullish narratives.
Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy?
Harmony Biosciences Holdings, Inc. (HRMY) is highlighted as a top small-cap value stock, with analysts reiterating Buy ratings and raising price targets due to positive discussions and a strong patent portfolio for its drug WAKIX. The company is actively developing new pitolisant formulations and accelerating research into Clemizole Hydrochloride for rare neurological diseases. While acknowledging HRMY's potential, the article also promotes a separate "cheapest AI stock" with significant upside.
[144] Harmony Biosciences Holdings, Inc. SEC Filing
A Form 144 notice was filed by Morgan Stanley Smith Barney LLC Executive Financial Services proposing the sale of 45,481 common shares of Harmony Biosciences Holdings, Inc. (HRMY). The filing indicates restricted stock vesting events totaling 24,521 shares on September 30, 2024, and 20,960 shares on April 14, 2026, as the nature of acquisition. The aggregate market value of the shares to be sold is $1,433,056.28.
Harmony Biosciences Holdings, Inc. (HRMY) Q1 earnings and revenues miss estimates
Harmony Biosciences Holdings, Inc. (HRMY) reported its Q1 earnings and revenue, both of which fell short of analyst estimates. This financial underperformance for the quarter could impact investor sentiment and future outlook for the company.
Do Upward Estimate Revisions Redefine Harmony Biosciences' (HRMY) Core Earnings Narrative After Q1 2026?
Harmony Biosciences (HRMY) recently reported Q1 2026 results, following upward revisions in earnings estimates by analysts. The company reaffirmed its 2026 net product revenue guidance, which is key to its investment narrative centered on WAKIX's profitability and cash flow, despite ongoing concentration risk with WAKIX. The article explores how these developments might impact the perception of Harmony Biosciences' future performance and fair value.
Harmony outlines $1B-$1.04B 2026 net revenue plan while targeting pitolisant GR PDUFA in Q1 2027
Harmony Biosciences Holdings (NASDAQ:HRMY) has provided its 2026 financial guidance, projecting net revenues of $1 billion to $1.04 billion, with expected growth in 2024 and 2025 as well. The company is actively expanding the clinical utility of pitolisant, targeting a PDUFA date for pitolisant GR in Q1 2027. Harmony's strategic plan emphasizes continued net revenue growth and pipeline development, aiming to solidify its market position.
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $85 at Oppenheimer
Oppenheimer analyst Andreas Argyrides raised the price target for Harmony Biosciences Holdings Inc. (HRMY) to $85.00 from $72.00, while maintaining an Outperform rating. The company's stock is currently priced at $31.42, showing a decline, with an overall rating trend that is down. This decision reflects the analyst's positive outlook on the company's future performance.
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q1 Revenue $215.4M, vs. FactSet Est of $220.8M
Harmony Biosciences Holdings, Inc. (HRMY) reported Q1 revenue of $215.4 million, falling short of FactSet's estimated $220.8 million. The company's stock symbol is HRMY, and it is a pharmaceutical company focused on treatments for rare neurological diseases. Harmony Biosciences also expects its 2026 WAKIX net revenue to range between $1.0 billion and $1.04 billion.
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 B
Harmony Biosciences reported Q1 2026 net product revenue of $215.4 million for WAKIX®, an increase of 17% year over year, and reaffirmed its full-year 2026 net revenue guidance of over $1 billion. The company outlined four strategic priorities: protecting the pitolisant franchise, growing the franchise in an evolving market, driving value from its pipeline including the BP-205 orexin-2 agonist, and renewing emphasis on business development. Harmony Biosciences also announced key personnel changes in its leadership team.
Harmony Biosciences (NASDAQ: HRMY) grows Q1 sales 17% and reaffirms $1B 2026 guidance
Harmony Biosciences reported a strong Q1 2026 with net product revenue for WAKIX reaching $215.4 million, a 17% increase year-over-year, and reaffirmed its full-year 2026 net revenue guidance of $1.0–$1.04 billion. Despite the revenue growth, net income decreased to $32.5 million due to higher R&D expenses and licensing agreement payments. The company highlighted strategic progress in intellectual property protection, lifecycle management for pitolisant (WAKIX), pipeline advancements including BP-205, and a renewed focus on business development opportunities.
Harmony Biosciences (NASDAQ: HRMY) grows Q1 2026 revenue but spends heavily on R&D
Harmony Biosciences reported increased net product revenue of $215.4 million in Q1 2026, up from $184.7 million in the prior year, primarily driven by WAKIX sales. However, net income decreased to $32.5 million from $45.6 million due to significantly higher research and development expenses, including $32.0 million for acquired in-process R&D and new license upfronts. Despite the lower profit, the company maintains a strong liquidity position with $870.5 million in cash and investments.
Harmony Biosciences : HRMY Q1 2026 Earnings Presentation
Harmony Biosciences (HRMY) presented its Q1 2026 earnings, highlighting a profitable and self-funded biotech with a robust pipeline and strong balance sheet. The company reaffirmed its 2026 net revenue guidance for WAKIX between $1.0B and $1.04B, driven by strong commercial performance and continued franchise growth. Harmony Biosciences also emphasized its renewed focus on business development, aiming to acquire assets in late-stage development or on the market to further drive growth.
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Harmony Biosciences reported Q1 2026 net product revenue of $215.4 million for WAKIX®, representing a 17% year-over-year increase, and reiterated its full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion. The company highlighted progress on four strategic priorities: protecting the pitolisant franchise, expanding its market presence with new formulations, advancing a robust pipeline including BP-205, and focusing on business development opportunities with revenue potential in the 2028–2032 timeframe. Harmony also announced new leadership appointments and detailed its financial performance, including a net income of $32.5 million for the quarter.
Do Upward Estimate Revisions Redefine Harmony Biosciences' (HRMY) Core Earnings Narrative After Q1 2026?
Harmony Biosciences Holdings recently reported Q1 2026 results following raised earnings estimates by analysts. The company reaffirmed its 2026 net product revenue guidance, signaling consistency despite ongoing reliance on its WAKIX product. This article examines how the increased analyst optimism and recent results influence Harmony Biosciences' investment narrative, while also noting the inherent risk of its WAKIX concentration.
Wall Street analysts think Harmony Biosciences (HRMY) could surge 34.81%: Read this before placing a bet
This article highlights that Wall Street analysts project a potential 34.81% upside for Harmony Biosciences (HRMY). It suggests investors review this analysis before making investment decisions. The information is presented as a quick insight into analyst expectations for the company's stock performance.
Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet
Harmony Biosciences (HRMY) stock closed at $31.83, having gained 14.7% in the past four weeks, with analysts setting a mean price target of $42.91, suggesting a 34.8% upside. This optimistic outlook is further supported by strong agreement among analysts regarding the company's earnings potential and a Zacks Rank #2 (Buy). However, investors are cautioned against relying solely on price targets, as they can often be overly optimistic due to analyst business incentives, and are advised to consider earnings estimate revisions as a more reliable indicator of near-term stock movement.
Harmony Biosciences Schedules First-Quarter Earnings Call for May 7
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will report its first-quarter 2026 financial results on Thursday, May 7, 2026, before the opening of U.S. financial markets. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss these results. Harmony Biosciences is a pharmaceutical company concentrating on developing and commercializing treatments for rare neurological diseases.
Capital Management Corp VA Sells 41,191 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Capital Management Corp VA reduced its stake in Harmony Biosciences Holdings, Inc. by 12.8% in Q4, selling 41,191 shares and now owning 281,721 shares valued at $10.54 million. Harmony Biosciences (NASDAQ:HRMY) stock is currently trading around $31.83 with a market capitalization of $1.84 billion and a P/E ratio of 11.75, following a Q4 EPS of $0.38 against a consensus of $0.84, though revenue topped expectations at $243.78 million. Analysts have a mixed outlook, with a consensus "Hold" rating and an average price target of $42.67, despite some recent downgrades.
CX Institutional Increases Position in Harmony Biosciences Holdings, Inc. $HRMY
CX Institutional significantly increased its stake in Harmony Biosciences Holdings, Inc. (HRMY) by nearly 20% in the fourth quarter, now owning 275,809 shares valued at over $10 million. Despite this, analysts have a mixed "Hold" consensus rating with an average target price of $42.67, and some firms recently downgraded the stock or cut target prices. Harmony Biosciences missed EPS estimates in its latest quarterly report but saw a 21.1% increase in revenue.
Price-Driven Insight from (HRMY) for Rule-Based Strategy
This article provides a price-driven insight for Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) using AI models to generate trading strategies. It highlights a neutral near-term outlook with potential mid-term strong sentiment stalling, identifies resistance testing, and outlines specific institutional trading strategies including long, breakout, and short setups with detailed entry, target, and stop loss zones. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Thursday
Harmony Biosciences (HRMY) is anticipated to report its Q1 2026 earnings before the market opens on Thursday, May 7th, with analysts projecting an EPS of $0.76 and revenue of $228.4 million. The company's prior quarter results showed a miss on EPS but a 21.1% year-over-year revenue increase. Currently, Harmony Biosciences holds a "Hold" consensus rating from analysts, with institutional investors owning a significant portion of its stock.
A Look At Harmony Biosciences (HRMY) Valuation After CFO Appointment And Reaffirmed 2026 Revenue Outlook
Harmony Biosciences (HRMY) recently appointed Glenn Reicin as CFO and reaffirmed its 2026 net product revenue outlook of US$1.0b to US$1.04b. Despite a decline in its 90-day share price return, the company has seen short-term momentum and is currently trading at US$31.05. Simply Wall St's analysis suggests the stock is 34.4% undervalued with a narrative fair value of $47.30, driven by potential revenue growth from pipeline catalysts, though risks like Wakix generic entry exist.
Harmony Biosciences Holdings (NasdaqGM:HRMY) Stock Forecast & Analyst Predictions
Harmony Biosciences Holdings is forecast to grow earnings by 11.8% and revenue by 6% annually. However, analyst price targets have been lowered recently to a $28-$36 range due to increased uncertainty surrounding Wakix patent trials and potential earlier generic entry. Despite some positive updates regarding revenue guidance and pipeline developments, concerns about long-term cash flows and exclusivity risks are impacting analyst sentiment.
Harmony Biosciences Appoints Glenn Reicin as CFO, Reaffirms Outlook
Harmony Biosciences (Nasdaq: HRMY) has appointed Glenn Reicin as its new chief financial officer, a move aimed at supporting the company's strategic growth and financial operations. Reicin will oversee financial planning, accounting, treasury, investor relations, and risk management. Concurrently, the company reaffirmed its 2026 net product revenue guidance of $1.0 billion to $1.04 billion, driven by projected Wakix sales.
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Harmony Biosciences Holdings, Inc. will report its first quarter 2026 financial results on Thursday, May 7, 2026, before the U.S. financial markets open. The company will also host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these results. Harmony Biosciences is a pharmaceutical company focused on developing and commercializing treatments for rare neurological diseases.
Ruffer LLP Purchases Shares of 40,993 Harmony Biosciences Holdings, Inc. $HRMY
Ruffer LLP has acquired 40,993 shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), marking a new stake worth approximately $1.54 million. This investment comes as Harmony Biosciences reported a quarterly EPS miss but a revenue beat, with institutional ownership remaining high at 86.23%. Analyst sentiment for HRMY is mixed, with a consensus "Hold" rating and an average target price of $42.67.
Harmony Biosciences sets May 7 investor call before market open
Harmony Biosciences (Nasdaq: HRMY) announced that it will release its first-quarter 2026 financial results on Thursday, May 7, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results. Investors can access the live and replay webcast on the company's investor relations website.
Harmony Bio granted FDA label expansion for Wakix in children with narcolepsy
This article reports that Harmony Biosciences received FDA label expansion for its drug Wakix (pitolisant) to treat excessive daytime sleepiness and cataplexy in children aged six and older with narcolepsy. This approval is based on positive results from the Phase 3 HARMONY trial, which demonstrated a significant reduction in weekly rates of these symptoms compared to placebo. Wakix is now positioned as a new treatment option for pediatric narcolepsy patients.
